Boston · Seed–Late Stage · 45 people tracked
Also known as 5AM VENTURE MANAGEMENT, LLC
Investment thesis
5AM Ventures backs life science and biotech companies, concentrating on biopharmaceuticals, drug delivery technologies, and life science instruments. Its main strategy invests in private, early-stage therapeutic companies with an emphasis on Series A financings, while an Opportunities strategy targets small and mid-cap public and later-stage private biotech and life science companies. Through its internal '4:59' effort, the firm takes a hands-on approach to discovering, incubating, and funding breakthrough science, partnering with academics and entrepreneurs and often acting as an extension of the operating team to generate proof-of-concept data that supports a Series A round.
Source: firm website, verified Aug 25, 2026.
Team · 45 people
from the firm's website & public directories
Founder mafia
4 people who came through 5AM Ventures went on to found or lead other companies.
What they invest in
from 51 of 102 portfolio companiesBiotech ×44Healthtech ×26Medical Devices ×9Deep Tech ×5Digital Health ×5AI & Machine Learning ×4Enterprise Software ×1FemTech ×1
HQs:United States×47
Who they back
founder profiles across 13 portfolio companiesFounding team size:solo founder×82 founders×33 founders×2
Investments · 102 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 32024 · 12023 · 12021 · 42020 · 22019 · 22018 · 32017 · 22016 · 42015 · 72014 · 131 dated
Entrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells.
BiotechHealthtechBoston, US
Nerissa Kreher(Executive Officer)Kory Wentworth(Executive Officer)inDipal Doshi(Chief Executive Officer)inNathan Dowden(Executive Officer)Natarajan Sethuraman, PhD(President of Research and Development)Nathan J. Dowden(President and Chief Operating Officer)in
Board seatKush M Parmar· per SEC Form D
Co-investorsMPM BioImpactRoche Venture FundTCG CrossoverAgent Capital
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for patients with autoimmune diseases.
BiotechHealthtechRadnor, US
Steven Nichtberger(Executive Officer, Director)Steven Nichtberger, MD(Founder)inDan Geffken(Executive Officer)Anup Marda(Chief Financial Officer)Mark Simon(Director)
Board seatBrian Daniels· per SEC Form D
BiotechCambridge, US
JOSH MANDEL-BREHM(Executive Officer, Director)RICHARD YOUNG(Director)
BoardMICHAEL HIGGINS(Director)JORGE CONDE(Director)inAMIR NASHAT(Director)in
Board seatAndrew J. SchwabAndy Schwab· per SEC Form D · filed Jun 2022
Co-investorsAndreessen HorowitzLongwood FundPolaris Partners
IDEAYA is a precision medicine oncology company developing first-in-class targeted therapies and rational drug combinations for molecularly defined, hard-to-treat cancers.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
Yujiro Hata(Executive Officer, Director)Paul Stone(Executive Officer)in
BoardTimothy Shannon(Director)inTerry Rosen(Director)Jeffrey Stein(Director)
Board seatJohn DiekmanBrian Daniels· per SEC Form D
Co-investorsCanaan PartnersNextech Invest
Pulmatrix develops inhaled dry-powder therapies using its proprietary iSPERSE technology, which uses small, dense, dispersible particles to deliver respiratory and non-respiratory drugs via the respiratory system.
BiotechDeep TechHealthtechMedical DevicesFramingham, US
Anand Varadan(Director)Richard Batycky(Director)Peter Ludlum(Interim CEO; Interim CFO)Hojabr Alimi(Executive Officer)Sameer Harish(Executive Officer)
BoardRichard Conley(Director)
Board seatScott Rocklage· per SEC Form D
Co-investorsARCH Venture PartnersPolaris Partners
Rallybio is a clinical-stage biotech company developing therapies for people with severe and rare diseases, with a pipeline focused on complement dysregulation and hematology.
BiotechHealthtechNew Haven, US
Steve Uden(Co-Founder & Chief Executive Officer)Stephen Uden(Founder)inMartin(Co-Founder & Chairman)Jon(Chief Financial Officer)
Board seatKush M ParmarPaula Soteropoulos· per SEC Form D
Co-investorsCanaan PartnersConnecticut InnovationsF-Prime CapitalMitsui Global InvestmentSolasta Ventures
BiotechBedford, US
Huw Nash(Executive Officer)Adrian Krainer(Executive Officer, Director, Promoter)Isabel Aznarez(Executive Officer, Director, Promoter)
Board seatArthur Tzianabos· per SEC Form D · $90M raise · filed Nov 2018
Arvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology.
BiotechHealthtechNew Haven, US
Sean Cassidy(Executive Officer)Manuel Litchman(Executive Officer, Director)
BoardStephen Squinto(Director)inLiam Ratcliffe(Director)Tim Shannon(Director)inKush Parmar(Director)
Co-investorsAccess BiotechnologyCanaan PartnersConnecticut InnovationsNextech InvestRA CapitalSolasta Ventures+1 more
Enliven Therapeutics is a biopharmaceutical company developing small molecule precision therapeutics, including ELVN-001, a selective active site inhibitor of BCR::ABL1 for patients with chronic myeloid leukemia (CML).
BiotechHealthtechBoulder, US
Co-investorsOrbiMedPfizer Venture InvestmentsRoche Venture FundARCH Venture Partners
Co-investorsOUP (Osage University Partners)RA Capital
Kinaset Therapeutics is a drug developer working on KN-002, a therapeutic candidate for treating severe asthma across patients regardless of the underlying cause of inflammation.
BiotechHealthtechMedfield, US
Roger Heerman(Chief Business/Operating Officer / Co-Founder)Frazer Morgan(Chief Development Officer / Co-Founder)Robert Clarke(Chief Executive Officer / Board Member / Co-Founder)Christopher O’Brien(Chief Medical Officer)
BoardJamil Beg(Director of the Issuer)inTom King(Director of the Issuer)
Co-investorsAtlas VentureRA CapitalEQT Life SciencesSixty Degree CapitalVivo CapitalGimv+1 more
Lifordi Immunotherapeutics develops treatments for immunology and rare diseases through discovery, clinical development, and commercialization.
BiotechDeep TechHealthtech
Arthur O. Tzianabos, Ph.D.(President and CEO)Naina Bhasin, Ph.D.(Chief Business Officer)
Co-investorsARCH Venture PartnersAtlas VentureSanofi Ventures
Precede Biosciences develops a blood-based diagnostic platform that profiles gene expression from cell-free DNA to reveal disease biology at the transcriptional level for drug developers and clinical trials.
AI & Machine LearningBiotechDigital HealthBoston, US
Rehan Verjee(Co-Founder, Chief Executive Officer, Board Director)Sylvan Baca(Co-Founder; Assistant Professor of Medicine, Dana-Farber Cancer Institute)Toni Choueiri(Co-Founder; Director, Lank Center for GU Oncology, Dana-Farber Cancer Institute)Matthew Freedman(Co-Founder; Professor of Medicine, Dana-Farber Cancer Institute)
Co-investorsIllumina VenturesOUP (Osage University Partners)Lilly Asia VenturesOsage University Partners
BlueLight Therapeutics uses a proprietary platform based on Second Harmonic Generation (SHG) to measure real-time structural changes of biomolecules, applying this structure-driven approach to discover and develop therapeutic molecules for difficult-to-drug, high-value targets.
BiotechDeep TechSouth San Francisco, US
Co-investorsPfizer VenturesPfizer Venture Investments
BiotechCambridge, US
G. Houston Hall(Manager of the Issuer)Adrian Z. Stecyk(Manager of the Issuer)Mark J. Pykett(Manager of the Issuer)
BoardAlexander M. Seaver(Manager of the Issuer)
Board seatArthur Tzianabos· per SEC Form D · $5M raise · filed Feb 2016
Akouos is a precision genetic medicine company developing therapies for the inner ear to restore, improve, and preserve hearing.
BiotechHealthtechBrookline, US
Emmanuel Simons(Executive Officer, Director)william sewell(Founder)in
BoardEd Mathers(Director)inKush Parmar(Director)in
Board seatKush M ParmarArthur Tzianabos· per SEC Form D
Co-investorsEcoR1 CapitalNew Enterprise Associates (NEA)RA CapitalSofinnova VenturesCowen Healthcare InvestmentsFidelity Investments+1 more
Artiva Biotherapeutics is a clinical-stage biotechnology company developing natural killer (NK) cell-based therapies for patients with autoimmune diseases.
BiotechHealthtechSan Diego, US
Jennifer Bush(Executive Officer)Yong-Jun Huh(Director)Thomas J. Farrell(Executive Officer)Yu-Kyeong Hwang(Director)Fred Aslan(Executive Officer, Director)Jason Litten(Executive Officer)
Board seatBrian Daniels· per SEC Form D
Co-investorsEcoR1 CapitalRA CapitalvenBio PartnersvenBio Global Strategic
La Jolla, US
Richa Nand(Executive Officer)Alan Glicklich(Executive Officer)Mark Saad(Executive Officer)Paul A. Grayson(Executive Officer, Director)Erik Karrer(Executive Officer)Ray Stevens(Director)
Board seatAndrew J. Schwab· per SEC Form D
Co-investorsSR One Capital Management
Pharmaceutical company developing medicines and vaccines for patient health and treatment.
BiotechHealthtechSan Diego, US
Jeffrey Stein(Executive Officer, Director)Kevin Judice(Director)Kevin Forrest(Executive Officer)Dirk Thye(Executive Officer)Ken Bartizal(Executive Officer)Paul Daruwala(Executive Officer)
Board seatScott Rocklage· per SEC Form D
Co-investorsAisling CapitalBain Capital Life SciencesFrazier Life SciencesRA CapitalVivo CapitalCanaan Partners+1 more
Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment.
BiotechHealthtechMedical DevicesBoston, US
Board seatKush M ParmarPaula Soteropoulos· per SEC Form D
Co-investorsAju IB Invesment CorporationCatalio Capital Management, LPDelos CapitalF-Prime CapitalSolasta VenturesAlexandria+7 more
BiotechBurlingame, US
John Celebi(Executive Officer)Mary Haak-Frendscho(Executive Officer, Director)
BoardCarl Gordon(Director)inDavid Goeddel(Director)Robert Schreiber(Director)
Board seatJohn Diekman· per SEC Form D · $6.3M raise · filed Jan 2015
Co-investorsOrbiMedThe Column Group
South San Francisco, US
Geoffrey Richardson(Executive Officer)Howard Turner(Executive Officer, Director)
BoardDipender Saluja(Director)Sam Bergh(Director)Suk-Bae Cha(Director)
Board seatScott Rocklage· per SEC Form D · $54.6M raise · filed Jun 2018
Co-investorsTechnology Impact
Latigo Bio is a clinical-stage biopharmaceutical company developing non-opioid pain medicines intended to block pain transmission without addiction risk.
BiotechHealthtechThousand Oaks, US
Nima Farzan(Executive Officer, Director)Tim Lugo(Executive Officer)
BoardBeth Seidenberg(Director)inJim Tananbaum(Director)Kevin Raidy(Director)
Board seatDeborah Palestrant· per SEC Form D · $150M raise · filed Feb 2025
Co-investorsAccess BiotechnologyForesite CapitalKern Capital, LLCSanofi VenturesWestlake Village BioPartners
Pioneering the development of prescription digital therapeutics.
HealthtechBoston, US
Corey McCann(Executive Officer, Director)Antoun Nabhan(Executive Officer)Christopher Guiffre(Executive Officer)
BoardAndrew Schwab(Director)inTimothy Petersen(Director)inZack Lynch(Director)in
Board seatAndrew J. Schwab· per SEC Form D · $20.4M raise · filed Feb 2016
Co-investorsJAZZ Venture PartnersArboretum VenturesGeneral CatalystOCA VenturesSeyen CapitalSoftBank Group+1 more
BiotechVancouver
Andrew Booth(Director)Andrew J. Schwab(Director)inR. James Taylor(Executive Officer, Director)Joe Victor(Executive Officer, Director)Euan Ramsay(Executive Officer)Daniel Nixon(Director)
Board seatAndrew J. Schwab· per SEC Form D · $13.4M raise · filed Nov 2016
Co-investorsRising TideTelegraph Hill Partners
BiotechLexington, US
Robert Clarke(Chief Executive Officer and Member of the Board of Directors)David Hava(Chief Scientific Officer)David Edwards(Director)
BoardSteven Gillis(Director)Terrance McGuire(Director)David Maki(Director)
Board seatScott Rocklage· per SEC Form D · $34.1M raise · filed Jun 2015
Co-investorsPolaris Partners
BiotechPleasanton, US
Bill W. Colston, Ph.D.(Director)Klint Rose, Ph.D.(Chief Scientific Officer)Barney E. Saunders,Ph.D.(Chief Executive Officer)Steve Reichenbach(Chief Financial Officer)Joseph J. Victor(Executive Chairman of the Board of Directors)Juan G. Santiago(Executive Officer, Director, Promoter)
Board seatJoseph J. Victor· per SEC Form D
Co-investorsCota CapitalRoche Venture Fund
Seattle, US
Ronald Seubert(Executive Officer, Director, Promoter)Evan Castiglia(Executive Officer)Joseph Victor(Executive Officer, Director)Frank Witney(Director)Eric Kaldjian(Executive Officer)
BoardRobert Shepler(Director)in
Board seatAndrew Schwab· per SEC Form D
Co-investorsArboretum VenturesF-Prime CapitalSofinnova VenturesTelegraph Hill Partners
Santa Clara, US
Thomas Boussie(Executive Officer)John Borkholder(Executive Officer)Robert Wedinger(Executive Officer, Director)Michelle Cheung(Executive Officer)Vince Murphy(Executive Officer)
BoardSamuel Colella(Director)
Board seatScott Rocklage· per SEC Form D
Co-investorsFrazier Life SciencesSofinnova Ventures
Alexza Pharmaceuticals, now operating as Nova Pneuma, Inc., is a pharmaceutical company that developed the Staccato One Breath Technology drug-delivery platform and markets the commercial product Adasuve.
BiotechHealthtechMountain View, US
Edwin S Kamemoto(Executive Officer)Mark K Oki(Executive Officer)Thomas B King(Executive Officer, Director)Michael J Simms(Executive Officer)James V Cassella(Executive Officer)Robert A Lippe(Executive Officer)
Co-investorsNew Enterprise Associates (NEA)
Co-investorsM Ventures
Co-investorsForesite Capital
Bioz provides AI-powered widgets for suppliers that display scientific publication data to build trust and improve sales conversion.
AI & Machine LearningEnterprise SoftwareSaaSLos Altos, US
Daniel Levitt(Executive Officer, Director)Karin Lachmi(Executive Officer, Director)Karin L.(Founder)in
Co-investorsPerot Jain
Co-investorsFrazier Life Sciences
Camp4 is a biotechnology company focused on genetic research and neurology, leveraging expertise in genomics and neuroscience for therapeutic development.
AI & Machine LearningBiotech
BoardChristopher Walsh, MD, PhD(Scientific Advisor)
Co-investorsAndreessen HorowitzFlucas Ventures
Co-investorsSofinnova Ventures
BiotechBurlingame, US
Mark Rolfe(Executive Officer)Laura Shawver(Executive Officer, Director)Timothy Smith(Executive Officer)
BoardAlfred Scheidegger(Director)inPeter Thompson(Director)Carol Gallagher(Director)
Co-investorsAstellas Venture Management LLCNew Enterprise Associates (NEA)Nextech InvestClarus VenturesOrbiMedOsage University Partners+1 more
Crinetics is a pharmaceutical company focused on discovering, developing, and commercializing therapies for endocrine diseases and endocrine-related conditions.
Biotech
Co-investorsOrbiMedRA Capital
Dianthus Therapeutics develops antibody-based therapies for patients with severe autoimmune diseases, including its lead complement C1s inhibitor claseprubart (DNTH103) and a bifunctional inhibitor DNTH212 designed for self-administered subcutaneous injection.
BiotechHealthtechWaltham, US
Jonathan Violin(Executive Officer, Director)Kenneth Evan Thompson(Executive Officer)
BoardLeon Moulder(Director)
Directed energy systems using AI-orchestrated high-power microwaves for electromagnetic defense.
Co-investorsBVVCCenter15 CapitalDCVC (Data Collective)Inflection VenturesManhattan Venture PartnersNightDragon+2 more
BiotechDel Mar, US
Matthew Disney(Director)Paul Stone(Executive Officer)inYujiro Hata(Director)Kevin Forrest(Executive Officer, Director)
BoardScott Rocklage(Executive Officer, Director)inJason Hafler(Director)in
Co-investorsKleiner PerkinsNovartis Venture FundSanofi Ventures
GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs.
BiotechHealthtechNewton, US
Ganesh V. Kaundinya(President & CEO)in
Co-investorsCatalio Capital Management, LPLifeArc VenturesRoche Venture FundSixty Degree CapitalSofinnova PartnersAgent Capital+1 more
Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.
BiotechBedford, US
Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)
BoardSteven Gillis(Director)Arthur Tzianabos(Executive Officer, Director)Kush Parmar(Director)inRichard Gregory(Director)
Co-investorsARCH Venture PartnersOUP (Osage University Partners)AlexandriaDeerfield Management CompanyHBM Healthcare InvestmentsMaverick Ventures+4 more
Co-investorsUS Venture Partners
HealthtechSeattle, US
John D. Hoekman(Executive Officer, Director)
BoardMichael Hite(Director)Stewart Parker(Director)
Co-investorsB Capital GroupvenBio Global StrategicvenBio PartnersWestlake Village BioPartners
Inipharm is a clinical-stage biopharmaceutical company developing small-molecule inhibitors targeting HSD17B13 to treat severe fibrotic liver diseases, including MASH and other conditions with established genetic validation.
BiotechHealthtechMedical Devices
Chuhan Chung(Chief Medical Officer)
Co-investorsFrazier Life Sciences
The page promotes "MEGA55", an Indonesian-language online gaming/gambling platform offering a variety of games with instant-win rewards and local digital payment methods.
Gaming
Co-investorsSanofi Ventures
Karius is a company that provides microbial cell-free DNA (mcfDNA) metagenomic sequencing services for research and clinical applications.
AI & Machine LearningBiotechDigital HealthMedical DevicesSan Francisco, US
Alec Ford(Chief Executive Officer)
Co-investorsDCVC (Data Collective)Khosla VenturesLightspeed Venture PartnersSoftBank Vision Fund
Magnetic Insight develops magnetic particle imaging technology that uses non-radioactive tracers as an alternative to conventional radioactive tracers used in nuclear medicine scans.
Deep TechHealthtechMedical Devices
Co-investorsInnolinks VenturesShangBay Capital LLC
Co-investorsLongwood Fund
nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.
BiotechDeep TechMedical Devices
Luke Gilbert, PhDKeith Joung, MD, PhDDavid Liu, PhDAngelo Lombardo, PhDLuigi Naldini, MD, PhDJonathan Weissman, PhD
Co-investorsAtlas VentureNewpath PartnersARCH Venture PartnersDCVC (Data Collective)F-Prime CapitalDCVC Bio+1 more
Neurogastrx is a late clinical-stage biopharmaceutical company developing therapies for patients with serious gastrointestinal (GI) disorders that have limited treatment options.
BiotechHealthtechWoburn, US
Cyril De Colle(Founder)inCYRIL DE COLLE(Executive Officer, Director)JAMES DETORE(Executive Officer)JAMES O'MARA(Executive Officer, Director)PAUL ROGERS(Executive Officer)
BoardDAVID ALLISON(Director)
Co-investorsOrbiMedSamsara BioCapitalvenBio PartnersVivo CapitalvenBio Global StrategicWestlake Village BioPartners
NodThera develops clinical-stage small-molecule therapies targeting inflammation for cardiometabolic and neuroinflammatory diseases, including cardiovascular disease, metabolic dysfunction, and neuroinflammation.
BiotechHealthtech
Geoff McDonough(Executive Team / Board)Chris Guiffre(Executive Team)Alan P. Watt(Executive Team)Jyothis George(Chief Medical Officer)Nick Clarke(Executive Team)
Co-investorsEpidarex CapitalF-Prime CapitalSanofi VenturesSofinnova Partners
Co-investorsAndera PartnersAngelini VenturesCDP Venture CapitalIndaco Venture PartnersM VenturesXGEN Venture
BiotechDoylestown, US
Osvaldo Flores(Executive Officer, Director)Daniel E. Geffken(Executive Officer)George Hartman(Executive Officer)Gregory Korbel(Executive Officer)
BoardTim Shannon(Director)Scott Rocklage(Director)
Co-investorsBioAdvanceCanaan PartnersVersant Ventures
South San Francisco biotech engineering commensal gut bacteria into controllable live therapeutics for chronic diseases.
Daly City, US
Weston Whitaker(Executive Officer, Director, Promoter)William DeLoache(Director)Samuel Smits(Director)
BoardElizabeth Stanley(Director)
Co-investorsAlta PartnersCerity Partners VenturesDCVC Bio
BiotechSeattle, US
ROBERT W. OVERELL(Executive Officer, Director, Promoter)PAUL JOHNSON(Executive Officer, Director)Michael Houston(Executive Officer)Andrew Leon(Executive Officer)Robert W. Overell(Executive Officer, Director, Promoter)Paul H. Johnson(Executive Officer, Director)
Radionetics develops small molecule radiopharmaceuticals that target GPCRs, using radioisotope-tethered ligands to image and treat cancerous tumors as part of a theranostics precision medicine approach.
BiotechMedical DevicesSan Diego, US
Co-investorsFrazier Life Sciences
Co-investorsHEALTHCARE ROYALTY PARTNERS
Renasant Bio is a biopharmaceutical company developing oral small molecule corrector and potentiator therapies to restore the function of polycystin 1 and 2 proteins in autosomal dominant polycystic kidney disease (ADPKD).
BiotechHealthtechBerkeley, US
Jeremy Reiter(Scientific Co-Founder)Markus Delling(Scientific Co-Founder)Thomas Gustafson(Executive Officer)Emily Conley(Executive Officer, Director)
BoardEvan Caplan(Director)inCharlotte McKee(Director)
Co-investorsOrbiMedAtlas VentureQiming Venture Partners USA
BiotechLexington, US
Pieter Muntendam(Executive Officer, Director)
BoardMette Kirstine Agger(Director)Kush Parmar(Director)inDorothy Coleman(Director)Leonard Schaeffer(Director)
BiotechSouth San Francisco, US
Anna Berkenblit(Director)Harold Varmus(Director)
BoardDavid Goeddel(Director)Craig Parker(Executive Officer, Director)Tim Kutzkey(Director)
Co-investorsThe Column Group
BiotechSan Diego, US
Alain Baron(Executive Officer, Director)JeenJoo Kang(Director)Robert Tjian(Director)Marcus Boehm(Executive Officer)
BoardAndrew Schwab(Director)in
Co-investorsAvego BioScience CapitalNew Enterprise Associates (NEA)OUP (Osage University Partners)Sanofi VenturesThe Column GroupAbingworth+3 more
TMRW Life Sciences builds an FDA-cleared automated platform for managing and storing frozen eggs and embryos, using RFID tracking and an "ivfOS" digital database to monitor and secure specimens.
Digital HealthFemTechHealthtechMedical DevicesNew York, US
Joshua Abram(Director)Tara Comonte(Director)Alan Murray(Director)
BoardAndrew Schwab(Director)Vinay Shah(Director)Emily Drabant Conley(Director)
Co-investorsGV (Google Ventures)
VBI Vaccines is a biopharmaceutical company developing vaccine candidates using virus-like particle (VLP) platforms, including proprietary enveloped VLP and mRNA-launched eVLP technologies.
BiotechHealthtechCambridge, US
Marc Kirchmeier(Vice President, Formulation Development)Egidio Nascimento(Chief Financial Officer)David Anderson(Senior Vice President, Research)Jeff Baxter(President and Chief Executive Officer)Adam T. Buckley(Vice President, Business Development)Murray G. Smith(Executive Officer)
Co-investorsARCH Venture PartnersClarus VenturesK2 HealthVentures
Viveve publishes evidence-based health and wellness guides for general readers across six topic areas including heart health, women's health, nutrition, hormones, sexual health, and aging.
Digital HealthMedia & EntertainmentWellness & Fitness
Co-investorsAvoro Capital Advisors
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 10
IPOs and acquisitions across the tracked portfolioEntrada Therapeutics, Inc.NASDAQ: TRDACabaletta BioNASDAQ: CABACamp4 Therapeutics CorpNASDAQ: CAMPIdeaya BiosciencesNASDAQ: IDYAPulmatrixNASDAQ: PULMRallybio, LLCNASDAQ: RLYBStoke TherapeuticsNASDAQ: STOKArvinas Holding Co. LLCNASDAQ: ARVNEnliven TherapeuticsNASDAQ: ELVNVor BiopharmaNASDAQ: VOR
Portfolio news
latest coverage across their companiesEnliven Therapeutics · tickerreport.com · Aug 21, 2026
Cidara Therapeutics · tradingkey.com · Aug 20, 2026
Dianthus Therapeutics · tickerreport.com · Aug 17, 2026
Latigo Bio · labusinessjournal.com · Aug 17, 2026
Crinetics · tipranks.com · Aug 14, 2026
Cabaletta Bio · stocktitan.net · Aug 14, 2026
Surrozen · simplywall.st · Aug 8, 2026
Stoke Therapeutics · finance.yahoo.com · Aug 7, 2026
Frequently asked questions
- How many investments has 5AM Ventures made?
- 5AM Ventures has 82 tracked investments, 2 of which have exited via acquisition or IPO, including 1 dated in the last 24 months.
- What stage does 5AM Ventures invest at?
- 5AM Ventures invests at the Seed, Series A, Growth, Late Stage stages.
- What is 5AM Ventures's typical check size?
- 5AM Ventures typically writes checks of $100K – $4M.
- What sectors does 5AM Ventures focus on?
- 5AM Ventures focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is 5AM Ventures located?
- 5AM Ventures is headquartered in Boston, US.
- Does 5AM Ventures lead rounds?
- Yes, 5AM Ventures leads investment rounds.
- Who does 5AM Ventures co-invest with?
- 5AM Ventures most often shares deals with RA Capital, Frazier Life Sciences, F-Prime Capital, among 51 tracked co-investors.
Co-investors · 40
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
venBio is a life sciences venture capital firm that partners with industry leaders to develop novel therapeutics and technologies addressing unmet medical needs.
▶28 more co-investors
The Column GroupNextech InvestWestlake Village BioPartnersAndreessen HorowitzSofinnova PartnersArboretum VenturesForesite CapitalConnecticut InnovationsLongwood FundTelegraph Hill PartnersKleiner PerkinsEQT Life SciencesVersant VenturesSR One Capital ManagementDeerfield Management CompanyAbingworthAndera PartnersAlta PartnersIllumina VenturesVenrockForbionFrazier Healthcare PartnersHatteras Venture PartnersNew Leaf Venture PartnersHealthQuest CapitalJMI EquityAltitude Ventures Management, LlcHive Ventures
Firms observed investing alongside 5AM Ventures, from public investor directories. Shared companies are the overlap with 5AM Ventures's recorded portfolio.
Similar investors
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.
Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.
EQT Life Sciences, formerly LSP, is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally. It is part of EQT Group.
Ally Bridge Group is a global healthcare investment manager focused on high-impact life sciences innovation across private and public markets.